ZEPOSIA® (ozanimod) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
It is not known if ZEPOSIA is safe and effective in children.
ZEPOSIA® (ozanimod) is a prescription medicine used to treat moderately to severely active ulcerative colitis (UC) in adults. It is not known if ZEPOSIA is safe and effective in children.
Terms and Conditions for the ZEPOSIA® (ozanimod) UC 360 Support SMS/Text Message Program
Upon registration, you will receive a confirmation text message. After activation, you can opt out at any time by texting STOP to 84592. You will receive one final text confirming your opt out request. Text HELP to 84592 for help. Message and data rates may apply.
Data obtained from you in connection with your registration for, and use of, this service may include your phone number and related carrier information. This data may be used to administer this Program and to provide Program benefits such as appointment reminders and alerts sent directly to your device.
The number of messages you receive will vary based on your responses. You may unsubscribe from the Program at any time by texting STOP to 84592.
Compatible carriers include: AT&T, T-Mobile®, Verizon Wireless, Sprint, Boost, U.S. Cellular, Cellular One, MetroPCS, ACS/Alaska, Bluegrass Cellular, Cellular One of East Central Illinois, Centennial Wireless, Cox Communications, EKN/Appalachian Wireless, GCI, Illinois Valley Cellular, Immix/Keystone Wireless, Inland Cellular, Nex-Tech Wireless, Rural Cellular Corporation, Thumb Cellular, United Wireless, West Central (WCC), Cellcom, Cellsouth, Cricket, Cincinnati Bell and Virgin Mobile.
For help, text HELP to 84592 or contact your mobile carrier. For questions about the Program, call 1-833-937-6742.
If you accidentally unsubscribe, or your mobile number changes, you may re-enroll in the mobile program via the method by which you may have originally enrolled.
Bristol Myers Squibb reserves the right to rescind, revoke, or amend the Program without notice.